(Mountain Standard Time)
6:00 PM - 8:00 PM
Course Directors' Reception
6:45 AM - 7:30 AM
Breakfast
7:30 AM - 8:00 AM
The Year 2024 In Review
8:00 AM - 8:10 AM
A Tribute To Stephen Harrison
SESSION 1: Outstanding Data From 2024
8:10 AM - 8:25 AM
Tirzepatide Phase 2b
8:25 AM - 8:40 AM
Semaglutide Primary Analysis Phase 3
8:40 AM - 8:55 AM
REGENERATE Long Term Outcome Data
8:55 AM - 9:10 AM
Survodutide Phase 2b
9:10 AM - 9:25 AM
Efruxifermin Harmony 96 Weeks/Pegozafermin 48 Week
9:25 AM - 9:40 AM
Panel Discussion
9:40 AM - 10:00 AM
Break - Exhibit Hall/Poster Viewing
SESSION 2: Deep Dive into Incretin and Endocrine Based Therapies
10:00 AM - 10:25 AM
Pleiotropic effects of FGF-21 in liver, brain and adipose tissue
10:25 AM - 10:45 AM
Thyromimetics: From Discovery to Biological Actions
10:45 AM - 11:05 AM
Incretins Mono and Pluri Agonists Which Ones Make Most Sense?
11:05 AM - 11:25 AM
GLP1 Agonists and PAN-PPAR-Agonists; Extrahepatic Benefits and Risks
11:25 AM - 11:45 AM
Panel Discussion
12:00 PM - 1:00 PM
CME Symposium
SESSION 3: Refining Clinical Benefit in Outcome Trials: Can CSPH Save Cirrhosis Trials?
4:00 PM – 4:20 PM
What Is CSPH and How Does It Change Prognosis?
4:20 PM – 4:40 PM
Non-Invasive Measurement of CSPH -Ready for Trial Time?
4:40 PM – 5:00 PM
How to Exclude Cirrhosis In Candidates For MASH Therapy With Resmetirom and MASH Trials
5:00 PM - 5:30 PM
Panel Discussion
5:30 PM - 5:50 PM
Break - Exhibit Hall/Poster Viewing
SESSION 4: The Promise of New Pharmacological Agents + Pathophysiology
5:50 PM - 6:00 PM
HSD17B13
6:00 PM - 6:10 PM
PNPLA3
6:10 PM – 6:20 PM
FASN inhibitors
6:20 PM - 6:30 PM
DGAT2 inhibitors
6:30 PM - 6:50 PM
State of the art: "Differential mechanisms in early vs late hepatic fibrosis and prospects for cirrhosis reversal"
6:50 PM - 7:05 PM
Top 5 Basic Science Papers in MASH
6:45 AM - 8:00 AM
Breakfast
SESSION 5: Can Digital Pathology Save MASH Trials?
8:00 AM - 8:20 AM
Recent Progress In Identifying Ballooned Cells and Resolution of Steatohepatitis With AI Assisted DP
8:20 AM - 8:40 AM
Recent Progress in Measuring Antifibrotic Effects:
Data From Clinical Trials I. (Histoindex and Clinician)
8:40 AM - 9:00 AM
Recent Progress In Measuring Antifibrotic Effects:
Data From Clinical Trials II. (Pharmanest And Clinician)
9:00 AM - 9:20 AM
AIM Explore : Assisting The Trials Vs Assisting The Clinician
9:20 AM - 9:40 AM
Panel Discussion: Digital Pathology In Clinical Trials How Long Before Regulatory Qualification?
9:40 AM - 10:00 AM
Break - Exhibit Hall/Poster Viewing
SESSION 6: The Case for MetALD
10:00 AM – 10:20 AM
Monitoring Alcohol Consumption In Clinical Trials: How And Why?
10:20 AM – 10:40 AM
Is MetALD An Impostor Or A Distinct Entity?
10:40 AM - 11:00 AM
The Case for MetALD Trials and How To Conduct Them
11:00 AM – 11:20 AM
Alcohol Use Disorder and How It May Interfere With MetALD Trials
11:20 AM - 11:45 AM
Panel Discussion
12:00 PM - 1:00 PM
CME Symposium
SESSION 7: Case Based Patient Journey
4:00 PM - 4:30 PM
Case Based Patient Journey
4:30 PM - 4:50 PM
Novel Genetics Approaches to Risk Statifications
4:50 PM - 5:10 PM
2 or 3 Oral Presentations
5:10 PM - 5:30 PM
Break—Exhibit Hall/Poster Viewing
SESSION 8: Surveying the Post Approval Landscape
5:30 PM - 5:50 PM
New Data on NIT Surrogates for MASH Trials
5:50 PM - 6:10 PM
Future of Combination Therapies
6:10 PM - 6:30 PM
How Did Clinical Practice Change with Resmetirom on the Market?
6:30 PM - 6:50 PM
Opportunities for Drug Development in the Resmetirom Era
6:50 PM - 7:10 PM
Panel Discussion
7:10 PM
Wrap Up
All Copyright © Reserved by MASH-TAG